Augmentation in RLS/PLMD
What is Augmentation?
In Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD), one of the most significant long-term risks associated with dopamine agonist medications is a phenomenon known as augmentation.
Augmentation does not mean an increase in medication dose. It refers to a worsening of the underlying condition itself. This may include symptoms becoming more severe, appearing earlier in the day, spreading to other parts of the body, or becoming more difficult to control with previously effective doses of medication.
Augmentation is distinct from the progression of Parkinson’s disease and is primarily associated with dopamine agonist treatment in RLS/PLMD. For some patients, augmentation may develop within weeks or months of starting treatment, while for others it may take many years to emerge.
How common is it?
The RLS Foundation Algorithm (updated May 2026) estimates that augmentation occurs in approximately 40–70% of patients treated with pramipexole or ropinirole over a 10-year period.
In fact, the updated RLS Foundation Algorithm reinforced the move away from dopamine agonists as a first-line treatment for RLS - read DAAG’s full summary and response, including practical advice for patients, here.
Symptoms
The Mayo Clinic treatment algorithm recommends considering augmentation in any patient whose RLS symptoms worsen while taking a stable dose of dopamine agonist medication, particularly where other causes have been excluded.
Possible signs of augmentation include:
RLS symptoms appearing earlier in the day than when treatment first began
Needing higher doses, earlier dosing, or additional medication to achieve the same symptom control
Increased intensity or severity of symptoms
Symptoms spreading to other body parts, such as the arms
Shorter duration of symptom relief between doses
Other factors can also worsen RLS symptoms and should be considered, including iron deficiency, certain medications known to worsen RLS symptoms, sleep deprivation and dietary factors.
Management of Augmentation
Management of augmentation requires empathy, patience and careful long-term planning. Dopamine agonists should not usually be discontinued abruptly, as withdrawal can lead to severe rebound RLS symptoms, profound insomnia, mood disturbance and symptoms consistent with Dopamine Agonist Withdrawal Syndrome (DAWS). During withdrawal, many patients require alternative treatments such as gabapentin, pregabalin or opioid medications to help manage symptoms.
The speed of withdrawal often needs to be individualised. Some patients tolerate more rapid dose reduction, while others may require slow tapering over many weeks or months. Many patients experience significant worsening of RLS symptoms during dose reduction, particularly following the final dose, and some report periods of extreme sleep deprivation and near-constant symptoms during withdrawal. Patients should be appropriately warned and supported through this process.
The Mayo Clinic treatment algorithm advises caution regarding repeated dopamine agonist dose escalation, long-acting dopamine agonist substitutions, drug rotations and “drug holidays” once augmentation has developed, due to concerns these approaches may worsen augmentation over time in some patients.
For more information, see our page on Dopamine Agonist Withdrawal Syndrome (DAWS).
Long-Term Treatment
Once dopamine agonists have been successfully discontinued, ongoing treatment requirements vary. Some patients are able to reduce alternative medications over time, while others - particularly those with severe or treatment-resistant RLS/PLMD, or where iron therapy alone is insufficient - may require long-term medication management.
Management plans should be individualised and regularly reviewed, taking into account both symptom control and the long-term risks associated with treatment.